Zhibing Wu, Qinghua Deng, Shenglin Ma, Ke Zhang, Kan Wu, Xiadong Li, Pengjun Zhao, Ruzhen Zheng
Hepatogastroenterology. 2013 Jul-Aug;60(125):989-94. doi: 10.5754/hge13038.
BACKGROUND/AIMS: The purpose of this study is to observe and compare the preliminary efficacy and side effects of docetaxel, 5-fluorouracil and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy for the treatment of advanced gastric cancer.
Retrospectively analyzed 101 patients with advanced gastric cancer receiving docetaxel, 5-fluorouracil, leucovorin and cisplatin intravenous chemotherapy or intravenous administration of docetaxel, 5-fluorouracil and leucovorin combined with cisplatin hyperthermic intraperitoneal perfusion chemotherapy, 49 patients in intravenous chemotherapy (VC) group, 52 patients in hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) group.
The response rate was 44.9% (22/49) in VC group and 65.4% (34/52) in HIPEC group, among which there was 1 case of CR, and the difference was statistically significant (p= 0.038). For CBR evaluation, the effective rate was 65.3% (32/49) in VC group and 82.7% (43/52) in HIPEC group, and the difference was statistically significant (p= 0.0458). The median progress free survival time (PFS) was 3.4 months in VC group and 4.6 months in HIPEC group, the difference was statistically significant (p= 0.045). The median overall survival time (OS) was 6.7 months in VC group and 7.5 months in HIPEC group, the difference was not statistically significant (p= 0.201). The main side effects in two groups were well tolerated, and there was no statistically significant difference.
The short-term efficacy and PFS of HIPEC plus intravenous chemotherapy were better than single intravenous chemotherapy, and there was no significant improvement in OS, the side effects were similar in two groups with good tolerability.
背景/目的：本研究旨在观察和比较多西他赛、5-氟尿嘧啶和亚叶酸钙静脉化疗联合顺铂热腹腔灌注化疗治疗晚期胃癌的初步疗效和副作用。
回顾性分析101例接受多西他赛、5-氟尿嘧啶、亚叶酸钙和顺铂静脉化疗或多西他赛、5-氟尿嘧啶和亚叶酸钙静脉给药联合顺铂热腹腔灌注化疗的晚期胃癌患者，静脉化疗（VC）组49例，热腹腔灌注化疗（HIPEC）组52例。
VC组有效率为44.9%（22/49），HIPEC组为65.4%（34/52），其中CR 1例，差异有统计学意义（p = 0.038）。CBR评估方面，VC组有效率为65.3%（32/49），HIPEC组为82.7%（43/52），差异有统计学意义（p = 0.0458）。VC组中位无进展生存期（PFS）为3.4个月，HIPEC组为4.6个月，差异有统计学意义（p = 0.045）。VC组中位总生存期（OS）为6.7个月，HIPEC组为7.5个月，差异无统计学意义（p = 0.201）。两组主要副作用耐受性良好，差异无统计学意义。
HIPEC联合静脉化疗的短期疗效和PFS优于单纯静脉化疗，OS无显著改善，两组副作用相似，耐受性良好。
